سعر جيمسيتابين اكتافيس 200 مجم فيال 2022

Gemcitabine 200 mg vial for intravenous infusion, pack of 1 vial; antineoplastic nucleoside metabolic inhibitor.

• Advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy, in combination with carboplatinPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• First-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy (unless anthracyclines were clinically contraindicated), in combination with paclitaxelPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• First-line treatment of inoperable locally advanced (stage IIIA or IIIB) or metastatic (stage IV) non-small cell lung cancer, in combination with cisplatinPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions with single-agent use (20% or more): nausea and vomiting, anaemia, increased ALT and AST, neutropenia, increased alkaline phosphatase, proteinuria, fever, haematuria, rash, thrombocytopenia, dyspnoea and oedema.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Patients with a known hypersensitivity to gemcitabine (reactions have included anaphylaxis).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Schedule-dependent toxicity: infusion longer than 60 minutes or dosing more often than weekly increases toxicity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Myelosuppression (neutropenia, thrombocytopenia, anaemia) can be severe; obtain a complete blood count with differential and platelet count before each dose and modify the dose as needed.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Pulmonary toxicity and respiratory failure (including interstitial pneumonitis, pulmonary fibrosis, pulmonary oedema and ARDS) can occur; discontinue permanently for unexplained new or worsening dyspnoea or evidence of severe pulmonary toxicity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Based on animal data and its mechanism of action, gemcitabine can cause fetal harm when given to a pregnant woman; there are no available data in pregnant women. Advise pregnant women of the potential risk to a fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment and for at least 1 week after the last dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.